Bladder cancer
Immunotherapy and antibody-drug conjugates: handling AEs and special populations
Objectif pédagogique: Get familiar with the current indications of immunotherapy and antibody-drug conjugates for metastatic urothelial carcinoma (UCa). Learn to identify patient characteristics that impact the appropriateness of immunotherapy and the antibody-drug conjugate enfortumab vedotin. Gain knowledge on how to handle adverse events (AEs).
Spécialité: Medical oncology, urology, clinical oncology, (radiation oncology)
Public cible: CME (basic, intermediate), Residents (senior)
Dernière mise à jour: July 2023
Contexte:
Regulatory approval status of drugs for metastatic UCa (status: 31 May 2023)
CPS: combined positive score